During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

The following is a summary of “FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 ...

especially if the cancer can’t be removed with surgery. PD-1 is a checkpoint protein on immune cells called T cells. When PD-1 attaches to PD-L1, a protein on other cells in the body, it acts as a ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

NICE says these patients taking Opdivo who had more PD-L1 (levels of 10% or more) on their cancer cells lived up to seven months longer than those with less. The committee have asked Bristol ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

Erdafitinib, also known as Balversa and made by Johnson & Johnson, is recommended in final draft guidance for adults with metastatic or unresectable FGFR-altered urothelial cancer who have previously ...

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...